The Production Process of (2β,4α,15α)-15-Hydroxy-2-[[2-O-(3-methyl-1-oxobutyl)-3,4-di-O-sulfo-β-D-glucopyranosyl]oxy]-19-norkaur-16-en-18-oic acid

The production process of (2β,4α,15α)-15-hydroxy-2-[[2-O-(3-methyl-1-oxobutyl)-3,4-di-O-sulfo-β-D-glucopyranosyl]oxy]-19-norkaur-16-en-18-oic acid, also known as Pristinamab, is a complex and multi-step process that involves the use of various chemicals, reagents, and equipment.
Pristinamab is an investigational monoclonal antibody drug that is being developed for the treatment of immune-related conditions such as lupus erythematosus and other autoimmune diseases.

The production process of Pristinamab involves several steps, including the cultivation of microorganisms, the purification of the antibody molecule, and the formulation of the final product.
The following is a detailed overview of the production process of Pristinamab.

1. Cultivation of Microorganisms

The production of Pristinamab begins with the cultivation of a specific type of bacteria, known as Escherichia coli, which is used as a host organism for the expression of the recombinant antibody molecule.
The E.
coli bacteria are engineered to express the genes responsible for the production of the antibody molecule, which is then expressed and secreted into the bacterial culture medium.

2. Purification of the Antibody Molecule

Once the E.
coli bacteria have express